Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

NCT06343376 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Manufacturing issues

Conditions

Recurrent Chronic Lymphocytic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Follicular Lymphoma
Recurrent High Grade B-Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Transformed Chronic Lymphocytic Leukemia
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Diffuse Large B-Cell Lymphoma
Refractory Follicular Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Mantle Cell Lymphoma
Refractory Transformed Chronic Lymphocytic Leukemia
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions

PROCEDURE: Biopsy
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Computed Tomography
DRUG: Cyclophosphamide
PROCEDURE: Echocardiography
BIOLOGICAL: EGFRt/19-28z/IL-12 CAR T-lymphocytes
DRUG: Fludarabine Phosphate
PROCEDURE: Leukapheresis
PROCEDURE: Multigated Acquisition Scan
PROCEDURE: Positron Emission Tomography

Sponsor

Roswell Park Cancer Institute